Shalby growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+5.0%+16.4%+16.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.7%−25.1%+29.5%
+8.9%−46.4%+40.8%
+1,706.6%−97.7%+23.4%
+1,694.4%−97.7%+23.3%
+8.0%+6.0%+25.5%
+1.0%−1.2%+8.6%
+99.8%−122.2%−71.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SHALBY₹121.96

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,311 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+16.0+16.4+5.0—
EBITDA Growth—+29.5-25.1+7.7—
EBIT Growth—+40.8-46.4+8.9—
Net Income Growth—+23.4-97.7+1,706.6—
EPS Growth—+23.3-97.7+1,694.4—
Total Assets Growth—+25.5+6.0+8.0—
Total Equity Growth—+8.6-1.2+1.0—
Cash from Operations Growth—-71.1-122.2+99.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.